- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Investigators evaluate treatment patterns in metastatic castration-sensitive prostate cancer
“What we found is that the use of these drugs and novel hormonal therapies and chemotherapy in the metastatic castration-sensitive setting was relatively low,” said Stephen J. Freedland, MD.
In this video, Stephen J. Freedland, MD, discusses the background and notable findings from the study, “Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019,” which was presented at the Western Section of the American Urological Association Annual Meeting. Freedland is the director of the Center for Integrated Research in Cancer and Lifestyle, co-director of the Cancer Genetics and Prevention Program, associate director for Faculty Development at the Samuel Oschin Comprehensive Cancer Institute, and professor of surgery at Cedar-Sinai in Los Angeles, California.
